Webinar: Rare diseases: Natural history studies for drug development
1:00:36
Description
Related Videos
View More
View Less
1:00:36
58:34
57:01
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
In this webinar, medical ethicists will discuss what investigators, ethics committees, IRBs and – ideally – sponsors can do to reverse this trend and create documents which achieve their intended purpose of allowing a child to understand their trial.
1:02:52
59:59
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03